Zokinvy
Zokinvy ingredients
| Active ingredient | Strength |
|---|---|
| Lonafarnib | 50 mg/1, 75 mg/1 |
What Zokinvy is used for
The FDA lists the approved uses on the official label (below). In the EU, lonafarnib is approved as Zokinvy for:
Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Zokinvy
- Generic name
- Lonafarnib
- Made by
- Sentynl Therapeutics, Inc.
- Forms
- Capsule
- Given
- Oral
- Drug class
- Farnesyltransferase Inhibitor
- FDA approval
- New drug application (NDA) NDA213969
- On the US market since
- 2025
Official information
- Zokinvy prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Lonafarnib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zokinvy?
Zokinvy (Lonafarnib) is a specialist medicine made by Sentynl Therapeutics, Inc., approved by the US FDA.
What are the ingredients of Zokinvy?
Zokinvy contains Lonafarnib (50 mg/1, 75 mg/1).
Is Zokinvy approved in Europe?
The same active substance is approved in the EU as Zokinvy.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA